Search alternatives:
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
linear decrease » linear increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
linear decrease » linear increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
421
-
422
-
423
-
424
-
425
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
Published 2022“…</p> <p><b>Conclusions:</b> Dulaglutide 1.5 mg treatment was statistically associated with a long-lasting decrease in HbA1c over 72 months, irrespective of baseline duration of diabetes, microvascular disease, and BMI.…”
-
426
-
427
-
428
-
429
Decreasing fatty acid saturation suppresses Δ<i>yhdP</i> Δ<i>fadR</i> cold sensitivity.
Published 2024“…<p><b>(A-C)</b> Lipids were extracted from cells grown to OD<sub>600</sub> 0.2 at 42°C then shifted to 30°C for 2 hours before harvest. …”
-
430
-
431
-
432
Decrease of Sun4 protein level upon <i>eIF2A</i> overexpression requires the presence of Ssd1.
Published 2023Subjects: -
433
Downregulation of DOM decreases the abundance of PER and TIM.
Published 2019“…<p><b>A.</b> Quantitative RT-PCR showing the expression of <i>clk</i>, <i>per</i> and <i>tim</i>. …”
-
434
<b>Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4</b>
Published 2025“…Greater decrease in LDL-cholesterol to 52 weeks predicted maintained weight loss. …”
-
435
-
436
-
437
-
438
-
439
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Published 2022“…Dapagliflozin led to a decrease in the risk of CVD/HHF, HHF and the cardiorenal outcome vs. placebo with no heterogeneity by baseline HbA1c (P-interaction >0.05).…”
-
440